These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15984108)

  • 21. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 22. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 23. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 24. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV; Barnett EM; Randels CL
    Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
    [No Abstract]   [Full Text] [Related]  

  • 25. Unnecessary withdrawal of Vioxx.
    Adams D
    N Z Med J; 2004 Oct; 117(1204):U1130. PubMed ID: 15505673
    [No Abstract]   [Full Text] [Related]  

  • 26. The Vioxx debacle revisited.
    Good CB; Kelley CL
    Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902
    [No Abstract]   [Full Text] [Related]  

  • 27. What happened to the coxibs on the way to the cardiologist?
    Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
    [No Abstract]   [Full Text] [Related]  

  • 28. COX-2 inhibitor use after Vioxx: careful balance or end of the rope?
    Fendrick AM
    Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

  • 30. Painful withdrawal for makers of Vioxx: pulling of arthritis drug raises questions on marketing, safety risks.
    Masters BA; Kaufman M
    Washington Post; 2004 Oct; ():A1, A8. PubMed ID: 15586941
    [No Abstract]   [Full Text] [Related]  

  • 31. Withdrawal syndrome.
    Nat Med; 2004 Nov; 10(11):1143. PubMed ID: 15516887
    [No Abstract]   [Full Text] [Related]  

  • 32. The coxib conundrum: lessons from the rise and fall of rofecoxib.
    Whelton A
    Am J Ther; 2004; 11(6):417-21. PubMed ID: 15543079
    [No Abstract]   [Full Text] [Related]  

  • 33. Withdrawal of rofecoxib - a wake up call for drug safety.
    Mishra P; Palaian S
    Kathmandu Univ Med J (KUMJ); 2004; 2(4):360. PubMed ID: 16388250
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval.
    Greener M
    EMBO Rep; 2005 Mar; 6(3):202-4. PubMed ID: 15741969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The lessons of Vioxx.
    Weinberg JM
    Cutis; 2005 Jan; 75(1):17. PubMed ID: 15732429
    [No Abstract]   [Full Text] [Related]  

  • 36. Keeping science on top in drug evaluation.
    Avorn J
    N Engl J Med; 2007 Aug; 357(7):633-5. PubMed ID: 17699813
    [No Abstract]   [Full Text] [Related]  

  • 37. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 38. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
    Roth-Cline MD
    Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.